journal article·2022-12Open access

Positively charged nanocomplex modulates dendritic cell differentiation to enhance Th1 immune response

Yan-Wei Wu, Wan-Yu Wang, Yu-Hung Chen

Abstract

Most existing vaccines use activators that polarize the immune response to T-helper (Th) 2 response for antibody production. Our positively charged chitosan (Cs)-based nanocomplex (CNC) drives the Th1 response through unknown mechanisms. As receptors for the positively charged CNC are not determined, the physico-chemical properties are hypothesized to correlate with its immunomodulatory effects. To clarify the effects of surface charge and size on the immune response, smaller CNC and negatively charged CNC encapsulating ovalbumin are tested on dendritic cell (DC) 2.4 ​cells. The negatively charged CNC loses activity, but the smaller CNC does not. To further evaluate the material effects, we replace Cs by poly-amino acids. Compared with the negatively charged nanocomplex, the positively charged one preserves its activity. Using immature bone marrow-derived DCs (BMDC) enriched from BALB/c mice as a model to analyze DC differentiation, treatments with positively charged nanocomplexes evidently increase the proportions of Langerin+ dermal DC, CD11blo interstitial DC, and CD8a+ conventional DC. Additionally, vaccination with two doses containing positively charged nanocomplexes are safe and increase ovalbumin-specific IgG and recall T-cell responses in mice. Overall, a positive charge seems to contribute to the immunological effect of nanocomplexes on elevating the Th1 response by modulating DC differentiation.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Immunotherapy and Immune Responses · T-cell and B-cell Immunology · Immune Cell Function and Interaction

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (46)

Show source-provided references
1. Recent advances in polymeric drug delivery systems10.1186/s40824-020-00190-7 ↗
2. Biodegradable polymers for gene-delivery applications10.2147/IJN.S222419 ↗
3. Biodegradable nanoparticles for drug and gene delivery to cells and tissue10.1016/S0169-409X(02)00228-4 ↗
4. Chitosan nanoparticles prepared by ionotropic gelation: an overview of recent advances10.1615/CritRevTherDrugCarrierSyst.2016014850 ↗
5. Immunomodulatory properties of chitosan polymers10.1016/j.biomaterials.2018.08.054 ↗
6. Potential Zika vaccine: encapsulated nanocomplex promotes both TH1/TH2 responses in mice
7. Chitosan but not chitin activates the inflammasome by a mechanism dependent upon phagocytosis10.1074/jbc.M111.274936 ↗
8. From secretome analysis to immunology: chitosan induces major alterations in the activation of dendritic cells via a TLR4-dependent mechanism10.1074/mcp.M800589-MCP200 ↗
9. Effect of chitosan properties on immunoreactivity10.3390/md14050091 ↗
10. Nanotechnology for the biologist10.1189/jlb.0205074 ↗
11. Immunological properties of engineered nanomaterials10.1038/nnano.2007.223 ↗
12. The instructive role of dendritic cells on T-cell responses10.1186/ar567 ↗
13. Helper T cell differentiation10.1038/s41423-019-0220-6 ↗
14. Modified chitosan-based nanoadjuvants enhance immunogenicity of protein antigens after mucosal vaccination10.1016/j.ijpharm.2019.118592 ↗
15. Chitosan nano-structure loaded with recombinant E. coli O157:H7 antigens as a vaccine candidate can effectively increase immunization capacity10.1080/21691401.2019.1629947 ↗
16. Single-injecting, bioinspired nanocomposite hydrogel that can recruit host immune cells in situ to elicit potent and long-lasting humoral immune responses10.1016/j.biomaterials.2019.119268 ↗
17. Innate sensing of chitin and chitosan10.1371/journal.ppat.1003080 ↗
18. Phagocytosis and antigen presentation in dendritic cells10.1111/j.1600-065X.2007.00552.x ↗
19. Nanotechnol. The effect of nanoparticle uptake on cellular behavior: disrupting or enabling functions?
20. Uptake efficiency of surface modified gold nanoparticles does not correlate with functional changes and cytokine secretion in human dendritic cells in vitro10.1016/j.nano.2014.11.004 ↗
21. More than one reason to rethink the use of peptides in vaccine design10.1038/nrd2224 ↗
22. Annu. The dendritic cell lineage: ontogeny and function of dendritic cells and their subsets in the steady state and the inflamed setting10.1146/annurev-immunol-020711-074950 ↗
23. Dendritic cells: from ontogenetic orphans to myelomonocytic descendants10.1016/0167-5699(96)80544-5 ↗
24. Plasmacytoid dendritic cells: development, functions, and role in atherosclerotic inflammation
25. Development of conventional dendritic Cells: from common bone marrow progenitors to multiple subsets in peripheral tissues10.1038/mi.2017.8 ↗
26. Identification of a novel cell type in peripheral lymphoid organs of mice. I. Morphology, quantitation, tissue distribution10.1084/jem.137.5.1142 ↗
27. Cloned dendritic cells can present exogenous antigens on both MHC class I and class II molecules10.4049/jimmunol.158.6.2723 ↗
28. Immature dendritic cells generated with low doses of GM-CSF in the absence of IL-4 are maturation resistant and prolong allograft survival in vivo10.1002/1521-4141(200007)30:7<1813::AID-IMMU1813>3.0.CO;2-8 ↗
29. Regulation of dendritic cell development by GM-CSF: molecular control and implications for immune homeostasis and therapy10.1182/blood-2011-11-370130 ↗
30. Transcriptional programming of the dendritic cell network10.1038/nri3149 ↗
31. Dendritic cell subsets in T cell programming: location dictates function10.1038/s41577-018-0088-1 ↗
32. Endocytosis and exocytosis of nanoparticles in mammalian cells
33. Vitro Determination of the immunogenic impact of nanomaterials on primary peripheral blood mononuclear cells10.3390/ijms21165610 ↗
34. Chemically engineered immune cell-derived microrobots and biomimetic nanoparticles: emerging biodiagnostic and therapeutic tools10.1002/advs.202002499 ↗
35. Cytokine secreting microparticles engineer the fate and the effector functions of T-cells10.1002/adma.201703178 ↗
36. The impact of nanoparticle protein corona on cytotoxicity, immunotoxicity and target drug delivery10.2217/nnm.15.188 ↗
37. Dendritic cells revisited10.1146/annurev-immunol-061020-053707 ↗
38. Identification of proliferating dendritic cell precursors in mouse blood10.1084/jem.175.5.1157 ↗
39. GM-CSF mouse bone marrow cultures comprise a heterogeneous population of CD11c(+)MHCII(+) macrophages and dendritic cells10.1016/j.immuni.2015.05.018 ↗
40. Plasmacytoid dendritic cells develop from Ly6D(+) lymphoid progenitors distinct from the myeloid lineage10.1038/s41590-019-0420-3 ↗
41. Current concepts of antigen cross-presentation10.3389/fimmu.2018.01643 ↗
42. Brief update on endocytosis of nanomedicines10.1016/j.addr.2019.08.004 ↗
43. Monocyte-derived DC maturation strategies and related pathways: a transcriptional view10.1007/s00262-010-0954-6 ↗
44. Dendritic cells and cytokines in human inflammatory and autoimmune diseases10.1016/j.cytogfr.2007.10.004 ↗
45. Dendritic cell homeostasis10.1182/blood-2008-12-180646 ↗
46. The CD8+ dendritic cell subset10.1111/j.0105-2896.2009.00870.x ↗